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BACKGROUND: Characterisation of EWS-Oct-4 translocation fusion product in bone and soft-tissue tumours revealed a chimeric gene
resulting from an in-frame fusion between EWS (Ewing’s sarcoma gene) exons 1–6 and Oct-4 exons 1–4. Recently, an alternative
form of the fusion protein between the EWS and Oct-4 genes, named EWS-Oct-4B, was reported in two types of epithelial tumours,
a hidradenoma of the skin and a mucoepidermoid carcinoma of the salivary glands. As the N-terminal and POU domains of the EWS-
Oct-4 and EWS-Oct-4B proteins are not structurally identical, we decided to investigate the functional consequences of the EWS-
Oct-4B fusion.
METHODS: In this report, we have characterised the EWS-Oct-4B fusion protein. To investigate how the EWS-Oct-4B protein
contributes to tumourigenesis in human cancers, we analysed its DNA-binding activity, subcellular localisation, transcriptional
activation behaviour, and oncogenic properties.
RESULTS: We found that this new chimeric gene encodes a nuclear protein that binds DNA with the same sequence specificity as the
parental Oct-4 protein or the fusion EWS-Oct-4 protein. We show that the nuclear localisation signal of EWS-Oct-4B is dependent
on the POU DNA-binding domain, and we identified a cluster of basic amino acids,
269RKRKR
273, in the POU domain that specifically
mediates the nuclear localisation of EWS-Oct-4B. Comparison of the properties of EWS-Oct-4B and EWS-Oct-4 indicated that
EWS-Oct-4B is a less-potent transcriptional activator of a reporter construct carrying the Oct-4-binding sites. Deletion analysis of the
functional domains of EWS-Oct-4B revealed that the EWS N-terminal domain (NTD)
B, POU, and C-terminal domain (CTD) are
necessary for its full transactivation potential. Despite its reduced activity as a transcriptional activator, EWS-Oct-4B regulated the
expression of fgf-4 (fibroblast growth factor-4) and nanog, which are potent mitogens, as well as of Oct-4 downstream target genes,
the promoters of which contain potential Oct-4-binding sites. Finally, ectopic expression of EWS-Oct-4B in Oct-4-null ZHBTc4 ES
cells resulted in increased tumourigenic growth potential in nude mice.
CONCLUSION: These results suggest that the oncogenic effect of the t(6;22) translocation is due to the EWS-Oct-4B chimeric protein,
and that alternative fusion of the EWS amino terminal domain to the Oct-4 DNA-binding domain produces another transforming
chimeric product in human epithelial tumours.
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Cancer is an abnormal type of tissue growth in which cells
proliferate in an uncontrolled, relatively autonomous manner,
leading to a continual increase in the number of dividing cells.
Chromosomal translocations cause cancer by activating existing
genes or creating new fusion proteins (Rabbitts, 1999). Some bone
and soft-tissue tumours were shown to harbour a translocation
t(6;22)(p21;q12) involving Ewing’s sarcoma (EWS) gene at 22q12
and the Oct-4 gene at 6p21 (Yamaguchi et al, 2005). Striking
features of these tumours are the diffuse proliferation pattern
of the undifferentiated tumour cells and the positive immuno-
reactivity for vimentin, S-100, and neuron-specific enolase.
A chimeric transcript of B1.8kb was detected by northern
blotting using EWS and Oct-4 probes, and an EWS-Oct-4 fusion
transcript, but not the reciprocal Oct-4-EWS fusion transcript, was
detected in tumours by RT–PCR (Yamaguchi et al, 2005).
Recently, a new fusion between EWS and Oct-4 was reported in
hidradenoma of the skin and mucoepidermoid carcinoma of the
salivary glands (Moller et al, 2008). Reverse transcription-PCR and
DNA sequence analyses revealed that a part of exon 6 of EWS is
fused in-frame to exon 2 of Oct-4 in these tumours, which
indicated that an alternative form of EWS-Oct-4 exists owing to a
variation in the locations of the EWS and Oct-4 genomic break
points. To distinguish it from the previous EWS-Oct-4 fusion
detected in human bone and soft-tissue tumours (Yamaguchi et al,
2005), we called it EWS-Oct-4B.
The EWS gene encodes a 656 amino acid protein that contains
three arginine- and glycine-rich tracts and an 85 amino acid RNA
recognition motif at its C-terminus. The N-terminal domain (NTD)
(amino acid 1–285) of EWS is composed almost exclusively
(B90%) of tyrosine, glycine, alanine, serine, threonine, and
proline residues organised in a repeated and degenerate
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spolypeptide motif with the consensus, NSYGQQS. This domain has
weak homology to the C-terminal region of eukaryotic RNA
polymerase II (Delattre et al,1 9 9 2 ) .T h eEWS gene is involved in
several tumour-related translocations, which generate fusions with
genes for putative transcription factors (Kim and Pelletier, 1999). In
each case, the translocation produces chimeric molecules containing
the NTD of EWS fused to the DNA-binding domain of the partner
protein. The C-terminal fusion partners are cellular transcription
factors that contribute a sequence-specific DNA-binding domain,
which determines the tumour phenotype (Lee, 2007). The highly
tissue-restricted expression of the fusion partners contrasts with
that of the native EWS gene, which is expressed ubiquitously at high
levels. The EWS promoter drives the expression of EWS fusion
proteins directly in human cancers owing to the genomic structure
of the EWS chimeras (Lin et al,1 9 9 9 ) .
Oct-4, also referred to as Oct-3, is a transcriptional regulator of
genes involved in maintaining the undifferentiated pluripotent
state, and may prevent the expression of genes activated during
differentiation (Brehm et al, 1997). It functions as a master switch
during differentiation by regulating gene expression in pluripotent
cells, or in cells that can develop pluripotent potential (Ovitt and
Scholer, 1998; Pesce and Scholer, 2001). In addition, Oct-4 is a key
factor in the genesis of human testicular germ cell tumours
(TGCTs) (Gidekel et al, 2003; Looijenga et al, 2003). Human
TGCTs are the most common malignancy in adolescent and young
adult Caucasian males, and are the cause of one in seven deaths in
this group (Oliver, 1999; Hellerstedt and Pienta, 2003). The Oct-4
transcript is consistently detected in a specific set of human TGCTs
found in adolescents and young adults, namely, seminomas and
embryonal carcinomas (Palumbo et al, 2002). In addition, the
precursor lesions of human TGCT, known as carcinoma in situ,
also express Oct-4 (Palumbo et al, 2002). Expression of Oct-4 has
also been reported in human primary breast carcinomas, human
breast cancer cell lines, and other types of carcinoma cell lines,
suggesting that its involvement in tumourigenesis may be related
to the upregulation of its downstream target genes (Jin et al, 1999;
Monk and Holding, 2001; Gidekel et al, 2003; Wang et al, 2003).
Consistent with these findings, Oct-4 expression in a heterologous
cell system transformed nontumourigenic cells and produced
tumours in nude mice. Activation of Oct-4 in adult mice using a
doxycycline-dependent expression system resulted in dysplastic
growth of epithelial tissues that are dependent on continuous
Oct-4 expression (Hochedlinger et al, 2005). In addition, Oct-4 is
involved in the reprogramming of mouse and human somatic cells
to the pluripotent state (Takahashi and Yamanaka, 2006; Okita
et al, 2007; Takahashi et al, 2007; Wernig et al, 2007, 2008; Aasen
et al, 2008; Dimos et al, 2008; Hockemeyer et al, 2008; Lowry et al,
2008; Maherali et al, 2008; Nakagawa et al, 2008; Park et al,
2008a,b), suggesting that induced pluripotent stem cells, derived
from somatic cells of patients, represent a powerful tool for use in
replacement therapies (Soldner et al, 2009).
To investigate how the recently identified EWS-Oct-4B protein
contributes to tumourigenesis in two types of human epithelial
tumours, namely, hidradenoma of the skin and mucoepidermoid
carcinoma of the salivary glands, we analysed its transcriptional
activation behaviour and oncogenic properties. We found that it is
a nuclear protein that binds DNA with a sequence specificity
indistinguishable from that of the parental Oct-4 or the chimeric
EWS-Oct-4 proteins. The nuclear localisation signal (NLS) of EWS-
Oct-4B was dependent on the POU DNA-binding domain, and we
identified a cluster of basic amino acids,
269RKRKR
273, in the POU
domain that specifically mediates the nuclear localisation of EWS-
Oct-4B. When we compared transactivation of reporter constructs
carrying Oct-4-binding sites by the different EWS-Oct-4 proteins,
EWS-Oct-4B was a less-potent transcriptional activator than EWS-
Oct-4. Results from deletion analysis also suggested that several
functional domains of EWS-Oct-4B are necessary for it to achieve
its full activation potential. However, although EWS-Oct-4B is a
less-potent transcriptional activator than EWS-Oct-4, it functions
as a dominantly acting oncogene, as measured by the activation of
oncogenic Oct-4 downstream target genes and tumour formation
in nude mice. These data indicate that EWS-Oct-4B may have a
critical role in the formation of human epithelial tumours by
activating the transcription of Oct-4 target genes.
MATERIALS AND METHODS
Molecular cloning
To generate pcDNA3/Flag-EWS-Oct-4B, we used the QuikChange
site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA), the
mutagenic primer set 50-EOB (50-AACTACAGTTATCCCCAGTCCC
AGGACATCAAAGCTC-30) and 30-EOB (50-ACGTTTGATGTCC
TGGGACTGGGGATAACTGTAGTTAC-30), and pKSII/Flag-EWS-
Oct-4 (Lee et al, 2007) as a template to construct pKSII/Flag-EWS-
Oct-4B. Then, pKSII/Flag-EWS-Oct-4B was digested with EcoRI
and HindIII and cloned into the corresponding sites of the
pcDNA3 vector (Invitrogen Molecular Probes, Carlsbad, USA).
The GST-EGFP-EWS-Oct-4B deletion mutants were generated
as follows: (A) pGST-EGFP, details on the construction of
pGST-EGFP have been previously reported (Kim et al, 2008); (B)
pGST-EGFP/EWS (NTD)
B, an EWS (NTD)
B fragment was amplified
from pcDNA3/EWS-Oct-4B by PCR using primers 50-GST-EGFP-
EWS(N) (50-GATCGGATCCAGCGTCCACGGATTACAG-30; BamHI
site underlined) and 30-GST-EGFP-EWS(N) (50-GATCGGATCC
AGCTGGGGATAACTGTAG-30; BamHI site underlined), digested
with BamHI, and cloned into the corresponding site of the
pGST-EGFP vector to generate pGST-EGFP/EWS (NTD)
B; (C)
pGST-EGFP/POU
B, a POU
B fragment was amplified from pcDNA3/
EWS-Oct-4B by PCR using primers 50-GST-EGFP-POU (50-GATC
GGATCCATCCCAGGACATCAAAGC-30; BamHI site underlined)
and 30-GST-EGFP-POU (50-GATCGGATCCAGGCTTGATCGCTTG
CCC-30; BamHI site underlined), digested with BamHI, and cloned
into the corresponding site of the pGST-EGFP vector to generate
pGST-EGFP/POU
B; (D) pGST-EGFP-POU
B (LILIL), pcDNA3/EWS-
Oct-4B (LILIL), in which amino acids
269RKRKR
273 were substi-
tuted with
269LILIL
273, was generated using the QuikChange site-
directed mutagenesis kit (Stratagene) and the mutagenic primer
set 50-mNLS (50-CCCTCGTGCAGGCCCTAATCCTAATCCTAACC
AGTATCGAGAAC-30) and 30-mNLS (50-GTTCTCGATACTGGTTA
GGATTAGGATTAGGGCCTGCACGAGGG-30). To construct pGST-
EGFP/POU
B (LILIL), POU
B (LILIL) was amplified from pcDNA3/
EWS-Oct-4B (LILIL) by PCR using primers 50-GST-EGFP-POU and
30-GST-EGFP-POU, digested with BamHI, and cloned into the
corresponding site of pGST-EGFP; (E) pGST-EGFP/CTD, a C-
terminal domain (CTD) fragment was amplified from pcDNA3/
EWS-Oct-4B by PCR using primers 50-GST-EGFP-CTD (50-GATC
GGATCCAAGCGACTATGCACAACG-30; BamHI site underlined)
and 30-GST-EGFP-CTD (50-GATCGGATCCAGGTTTGAATGCATG
GGA-30; BamHI site underlined), digested with BamHI, and cloned
into the corresponding site of the pGST-EGFP vector to generate
pGST-EGFP/CTD.
To construct pGAL4-EWS (NTD), an EWS fragment (amino acid
1–193) was amplified from pcDNA3/Flag-EWS-Oct-4 by PCR
using primers 50-E-OFlagEcoRI (50-GATCGAATTCATGGATTA-
CAAGGATGAC-30; EcoRI site underlined) and 30-EWSBamHI
(50-GATCGGATCCTAGGTAGGAGGGTAGGATGG-30; BamHI site
underlined), digested with EcoRI and BamHI, and cloned into
the corresponding sites of the pM vector (Clontech Laboratories,
Mountain View, CA, USA). To construct pGAL4-EWS (NTD)
B,a n
EWS fragment (amino acid 1–174) was amplified from pcDNA3/
Flag-EWS-Oct-4 by PCR using primers 50-E-OFlagEcoRI and
30-EWS(B)BamHI (50-GATCGGATCCCTGGGGATAACTGTAGTT-
30; BamHI site underlined), digested with EcoRI and BamHI, and
cloned into the corresponding sites of the pM vector.
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sThe pcDNA3/Flag-EWS-Oct-4B deletion mutants were generated
as follows: (A) pcDNA3/Flag-EWS-Oct-4B (DEWS), a Flag-EWS-
Oct-4B (DEWS) fragment was amplified from pKSII/Flag-EWS-
Oct-4B by PCR using primers 50-FlagOct-4BPOU (50-GATCAA
GCTTATGGATTACAAGGATGACGACGATAAGTCCCAGGACATCA
AAGCTC-30; HindIII site underlined) and 30-EOEcoRI (50-GATCG
AATTCTCAGTTTGAATGCATGGG-30; EcoRI site underlined), diges-
ted with HindIII and EcoRI, and cloned into the corresponding
sites of the pcDNA3 vector to generate pcDNA3/Flag-EWS-Oct-4B
(DEWS); (B) pcDNA3/Flag-EWS-Oct-4B (DCTD), a Flag-EWS-Oct-4B
(DCTD) fragment was amplified from pKSII/Flag-EWS-Oct-4B by
PCR using primers 50-BamHIFlagE-O (50-GATCGGATCCATGGATTA
CAAGGATGAC-30; BamHI site underlined) and 30-hOct3A-867EcoRI
(50-GATCGAATTCGCTTGATCGCTTGCCCTT-30; EcoRI site under-
lined), digested with BamHI and EcoRI, and cloned into the
corresponding sites of the pcDNA3 vector to generate pcDNA3/
Flag-EWS-Oct-4B (DCTD); (C) pcDNA3/Flag-EWS-Oct-4B (V313P),
pCAG-IP/EWS-Oct-4 (V351P) (Kim et al, 2009) was digested with
EcoNI to isolate an EcoNI-V313P-EcoNI fragment. Then, pcDNA3/
Flag-EWS-Oct-4B was digested with EcoNI to generate pcDNA3/Flag-
EWS-Oct-4B (DEcoNI), and pcDNA3/Flag-EWS-Oct-4B (DEcoNI)
was ligated with the EcoNI-V313P-EcoNI fragment to generate
pcDNA3/Flag-EWS-Oct-4B (V313P).
Construct pCAG-IP/EGFP has been described previously (Lee
et al, 2006). To create pCAG-IP/EWS-Oct-4B-EGFP, EWS-Oct-4B
was amplified from pcDNA3/Flag-EWS-Oct-4B by PCR using
primers 50-BamHIFlagE-O (50-GATCGGATCCATGGATTACAAGG
ATGAC-30, BamHI site underlined) and 30-hOct4CTDGFP (50-GAT
CGGATCCGCTCCGTTTGAATGCATGGG-30, BamHI site under-
lined). The PCR product was digested with BamHI and cloned into
the same sites of the pEGFP (N1) vector (Clontech Laboratories) to
generate pEGFP(N1)-EWS-Oct-4B. To construct pCAG-IP/EWS-
Oct-4B-EGFP, the blunted HindIII (repaired with the Klenow
fragment) and NotI fragments of pEGFP(N1)-EWS-Oct-4B were
subcloned into the blunted XhoI (repaired with the Klenow
fragment) and NotI sites of the pCAG-IP vector.
Electrophoretic mobility shift assays
Probes (50-GGCACTTCACTAGCATAACAATGAGGGCTC-30 and
50-GAGCCCTCATTGTTATGCTAGTGAAGTGCC-30; underlines in-
dicate the Oct-4 recognition site) for electrophoretic mobility shift
assays (EMSAs) were prepared from synthetic oligonucleotides for
which the sequences have been described previously (Nishimoto
et al, 1999). The probe was prepared by end-labelling annealed
complementary oligonucleotides with [g-
32P] ATP using T4
polynucleotide kinase. The DNA-binding reactions were
performed using purified glutathione-S-transferase (GST),
GST-EWS-Oct-4, or GST-EWS-Oct-4B proteins for 30min at 41C
in binding buffer containing 10mM Tris-HCl (pH 8.0), 40mM KCl,
6% glycerol, 1mM DTT, 0.05% NP-40, and 10ngml
 1 of poly
(dI dC) (dI dC). After binding, the reaction mixtures were run on
4% polyacrylamide gels (acrylamide/bisacrylamide ratio. 37:1) in
0.5  TBE (44.5mM Tris-HCl, 44.5mM boric acid, 1mM EDTA)
buffer at 150V for 2–3h at 41C. The gels were dried and exposed to
Kodak X-Omat film (Kodak, Rochester, MN, USA) at  701C, using
an intensifying screen.
Transfection, subcellular localisation, and reporter gene
assays
Subcellular localisation experiments were performed as previously
described (Kim et al, 2008). Briefly, to examine the localisation
of the EWS-Oct-4B-EGFP or GST-EGFP fusion proteins of the
EWS-Oct-4B truncation mutants, cells were transfected with
pEGFP, pEWS-Oct-4B-EGFP, pGST-EGFP, pGST-EGFP/EWS
(NTD)
B, pGST-EGFP/POU
B, pGST-EGFP/POU
B (LILIL), or pGST-
EGFP/CTD using the VivaMagic reagent (Vivagen, Seoul, Korea),
Oct-4A
Oct-4B
360 290 133 1
265 11 9 5 40
(133 aa) (156 aa) (71 aa)
(40 aa) (154 aa) (71 aa)
EWS-Oct-4
EWS-Oct-4B
1 193
EWS (NTD) N POUA CTD
CTD
CTD
CTD POUA
POUB
POUB EWS (NTD)B
Extra 6 aa 194 199
210
211
367
366
399 13 2 9
328 175
174
(154 aa)
(71 aa)
(71 aa)
(156 aa) (193 aa)
(174 aa)
NTDB
NTDA
134 289
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437
Figure 1 Structural comparison of EWS-Oct-4 alternative forms. Two different forms of the EWS-Oct-4 protein (EWS-Oct-4 and EWS-Oct-4B) and the
human Oct-4 isoforms (Oct-4A and Oct-4B) are represented schematically. Amino acid (aa) positions are indicated above and below the schematic
representing the proteins. In the case of EWS-Oct-4, the first 193 aa (residues 1–193) of EWS are fused to the truncated coding sequence (residues
123–360) of Oct-4A through an additional six aa sequence. This six aa sequence is encoded by the normal intron 6 of EWS in the fusion transcript that lacks
the first 122 aa (residues 1–122) present in Oct-4A. In contrast, in the case of EWS-Oct-4B, the first 174 aa (residues 1–174) of EWS were fused to the
POU DNA-binding domain (residues 136–360) of Oct-4A, in which neither the additional six aa sequence nor the N-terminal domain of Oct-4A is retained
in EWS-Oct-4B. Functionally important domains of the Oct-4 isoforms and EWS-Oct-4 chimeras are indicated: NTD
A, the N-terminal domain of human
Oct-4A; POU
A, POU DNA-binding domain (total 156 amino acids) of human Oct-4A; CTD, C-terminal domain of Oct-4; NTD
B, N-terminal domain
of human Oct-4B; POU
B, POU DNA-binding domain (total 154 amino acids) of human Oct-4B; EWS (NTD), EWS N-terminal domain (residues 1–193)
of EWS-Oct-4; Extra 6 aa, extra six amino acids; N, truncated N-terminal domain of Oct-4; EWS (NTD)
B, EWS N-terminal domain (residues 1–174)
of EWS-Oct-4B.
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swashed in PBS, and then fixed for 10min at  201C in a mixture of
acetone and methanol (1:1, v/v). Coverslips were mounted with
50% glycerol/PBS, and the green fluorescence of EGFP was
detected using a fluorescence microscope (IX71, Olympus, Tokyo,
Japan) equipped with DP71 digital camera (Olympus). For reporter
gene assays, cells were transiently transfected with plasmids by
electroporation using the VivaMagic reagent (Vivagen). Luciferase
assays were performed with the Dual-luciferase Assay System
(Promega, Madison, WI, USA). Renilla luciferase activities were
used to normalise transfection efficiencies.
Western blot analysis
Western blot analysis was performed using anti-Oct-4 (C-20, Santa
Cruz Biotechnology, Santa Cruz, CA, USA), anti-EGFP (Invitrogen
Molecular Probes), anti-GST (B-14, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), anti-GAL4 (RK5C1, Santa Cruz Biotechnol-
ogy), anti-Flag (M2, Sigma, St Louis, MO, USA), and anti-GAPDH
(V-18, Santa Cruz Biotechnology) antibodies, and reactive bands
were detected by chemiluminescence using Western Lightening
(PerkinElmer Life Sciences, Boston, MA, USA).
Establishment of stable cell lines and tumourigenic assays
in nude mice
Details on the construction of ZHBTc4 ES cell line expressing
EGFP have been previously reported (Lee et al, 2006). To generate
stably expressing ES cell lines, pCAG-IP/EWS-Oct-4B-EGFP was
linearised with PvuI and 10mg of each was transfected into
ZHBTc4 ES cells (4 10
6) using the MicroPorator (Digital Bio,
Seoul, Korea). At 48h after electroporation, puromycin (Sigma)
was added to a final concentration of 1mgml
 1 to select clones
carrying stably integrated plasmid DNA. After selection of
transfected ZHBTc4 cells, monoclonal cell lines were isolated by
picking individual puromycin-resistant colonies. Tumourigenic
assays were performed in nude mice as previously described (Kim
et al, 1998a). In brief, 5-week-old athymic nude mice (CD1 nu/nu;
Charles River, Wilmington, MA, USA) were pre-treated with
tetracycline analogue doxycycline (10mgml
 1) in their drinking
water for 2 weeks before injection. Then, 0.6 10
7 cells from each
clone in 100ml PBS were injected subcutaneously into nude mice
and the mice continued to be exposed to doxycycline. Those mice
that developed tumours were killed after 26 days.
RESULTS
Structural features of EWS-Oct-4B
The EWS-Oct-4 chimeric gene was originally isolated from bone
and soft-tissue tumours (Yamaguchi et al, 2005). This chimeric
gene encodes a protein in which the first 122 amino acids present
in the NTD of Oct-4 are replaced by the N-terminal 193 amino
acids of EWS through an additional six amino acid sequence
encoded by the normal intron 6 of EWS (Figure 1). Recently, a
different type of EWS-Oct-4 chimeric transcript, EWS-Oct-4B, was
isolated in a hidradenoma of the skin and a mucoepidermoid
GST-EGFP/EWS (NTD)B
GST-EGFP/POUB
GST-EGFP/CTD
GST-EGFP GST EGFP
EWS(N)B GST EGFP
POUB GST EGFP
CTD GST EGFP
Cellular
localization
C
C
N
C
GST-EGFP/POUB (LILIL) POUB GST EGFP C
RKRKR LILIL
EGFP EWS-Oct-4B-EGFP
POUB Vector CTD EWS (NTD)B POUB (LILIL)
Figure 2 Mapping of the nuclear localisation signal of EWS-Oct-4B to the POU
B DNA-binding domain. (A) Subcellular localisation of EWS-Oct-4B. Cells
(293T) grown on coverslips were transfected with mammalian expression vectors encoding (a) EGFP or (b) EWS-Oct-4B-EGFP. The subcellular localisation
of the EWS-Oct-4B protein was determined by monitoring the location of the green fluorescence. (B) Schematic diagram showing EWS-Oct-4B truncation
mutants of GST-EGFP fusion proteins. Subcellular localisation of the indicated truncation mutants was determined by monitoring the location of green
fluorescence, and is indicated as N (nuclear localisation) or C (cytoplasmic localisation). (C) Subcellular distribution of EWS-Oct-4B deletion mutants. 293T
cells were grown on coverslips under low-density conditions and transfected with expression plasmids for the indicated GST-EGFP-EWS-Oct-4B deletion
mutants. The cells were fixed with an acetone/methanol mixture and EGFP was analysed by fluorescence microscopy.
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scarcinoma of the salivary gland (Moller et al, 2008). Sequence
analysis of the EWS-Oct-4B gene revealed that a part of EWS exon 6
was fused in-frame to exon 2 of Oct-4, but unlike the EWS-Oct-4
fusion found in bone and soft-tissue tumours, neither the
additional six amino acid sequence nor the NTD of Oct-4A was
retained in the EWS-Oct-4B fusion (Figure 1). In addition, the POU
domain of EWS-Oct-4B (POU
B, total 154 amino acids) lacks two
amino acids of the N-terminal sequence of the EWS-Oct-4 POU
domain (POU
A, total 156 amino acids). As a result of this parti-
cular chromosome translocation, the structure of the C-terminal
portion of EWS-Oct-4B is more similar to the human Oct-4B
isoform than to Oct-4A.
EWS-Oct-4B is a nuclear protein
We have shown previously that EWS-Oct-4 localises to the nucleus
(Lee et al, 2007). As the structure of EWS-Oct-4B is more similar to
human Oct-4B rather than to Oct-4A (Figure 1), and as Oct-4B is
mainly localised to the cytoplasm (Lee et al, 2006), we decided to
investigate the subcellular localisation of EWS-Oct-4B. As a first
step, we transfected 293T cells with the pEGFP-N1 vector or with
pEWS-Oct-4B-EGFP and carefully monitored the localisation of
green fluorescence. In the transiently transfected cells, EGFP-tagged
EWS-Oct-4B was clearly localised to the nucleus (Figure 2Ab), whereas
EGFP alone was found in both the nucleus and cytoplasm (Figure 2Aa).
These data indicate that EWS-Oct-4B is a nuclear protein, unlike
human Oct-4B, which is mainly localised to the cytoplasm.
To map the region of EWS-Oct-4B responsible for its nuclear
localisation, we generated a set of EWS-Oct-4B deletion mutants
(Figure 2B). Because polypeptides with molecular masses of
o40–50kDa can passively diffuse into the nucleus (Breeuwer
and Goldfarb, 1990), we fused the isolated functional domains of
EWS-Oct-4B to GST and EGFP. The 293T cells were transfected
with expression vectors for the GST-EGFP fusion proteins of
the EWS-Oct-4B truncation mutants, and the localisation of EGFP
was analysed by fluorescence microscopy. GST-EGFP/EWS (NTD)
B
(Figure 2Cb) and CTD (Figure 2Ce) localised to the cytoplasm,
whereas GST-EGFP/POU (Figure 2Cc) clearly localised to the
nucleus. GST-EGFP was used as a control and localised to the
cytoplasm of 293T cells (Figure 2Ca).
To define NLS further in the POU
B domain of EWS-Oct-4B,
we generated a POU
B mutant in which several highly conserved
basic amino acids,
269RKRKR
273, were replaced with the
269LILIL
273
sequence using site-directed mutagenesis. This region of basic
amino acids was chosen as a putative NLS on the basis of
earlier evidence that states that positively charged sequences are
good candidates for nuclear targeting signals (Dingwall and
Laskey, 1991). Consistent with our prediction, the substitution
of
269RKRKR
273 with the
269LILIL
273 sequence resulted in the cyto-
plasmic accumulation of GST-EGFP/POU
B (Figure 2Cd). This
result suggested that this cluster of basic amino acids in the
POU
B domain does indeed function as an NLS of EWS-Oct-4B.
EWS-Oct-4B is a less-potent transcriptional activator than
EWS-Oct-4
To assess the transactivation potential of EWS-Oct-4B, we
compared the transcription activities of EWS-Oct-4B and EWS-
Oct-4 by cotransfecting their respective expression vectors with a
reporter plasmid containing 10 copies of the Oct-4-binding site
and a TATA box upstream of the luciferase gene (Lee et al, 2005).
We also included a control plasmid consisting of a cytomegalo-
virus-driven Renilla luciferase gene. As shown in Figure 3,
cotransfected EWS-Oct-4B caused a 1100-fold increase in reporter
expression in 293T cells (Figure 3 top panel, bars 4 and 5)
compared with an B2700-fold increase by EWS-Oct-4 (Figure 3
top panel, bars 2 and 3). Our results indicate that EWS-Oct-4B is a
less-potent transcriptional activator than EWS-Oct-4. Western
blotting of cell extracts from transfected cells showed that
increasing amounts of EWS-Oct-4 and EWS-Oct-4B proteins were
synthesised in response to increasing amounts of the correspond-
ing plasmids (Figure 3 middle panel). In addition, western blot
analysis showed that the difference in transactivation potential
between EWS-Oct-4 and EWS-Oct-4B was not due to differences
in the amounts of these proteins. The EGFP expression plasmid
served as an internal control for monitoring transfection efficiency
(Figure 3 bottom panel).
EWS-Oct-4B similar to EWS-Oct-4 binds to an Oct-4
consensus sequence
The POU domain of Oct-4 is a conserved DNA-binding domain
that binds as a monomer to the octamer sequence motif, 50-AT
GCAAAT-30 (Botquin et al, 1998). Although there is consider-
able structural similarity between EWS-Oct-4B and EWS-Oct-4
(Figure 1), POU
B, the DNA-binding domain of EWS-Oct-4B, lacks
two amino acids of the N-terminal sequence found in the EWS-
Oct-4 POU domain (POU
A), and the structure of the EWS-Oct-4B
C-terminal portion (POU plus CTD) is more similar to that of the
Oct-4B isoform than to that of Oct-4A. Interestingly, the Oct-4B
isoform does not bind to a probe carrying the Oct-4 consensus-
binding sequence, and two separate regions of its NTD
are responsible for inhibiting DNA binding (Lee et al, 2006).
To determine whether EWS-Oct-4B binds the target sequence
of Oct-4, we performed EMSAs. An oligonucleotide containing
the consensus Oct-4 DNA-binding sequence (Botquin et al, 1998)
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Figure 3 Comparison of transactivation potential by EWS-Oct-4B. Cells
(293T) were cotransfected with expression vectors encoding the indicated
amounts of EWS-Oct-4 (grey bars) or EWS-Oct-4B (black bars), the pOct-
4(10 ) TATA luc reporter plasmid, and the Renilla luciferase (top panel).
Reporter activity was normalised with Renilla luciferase activity to correct
for different transfection efficiencies. Fold induction is expressed relative to
the empty expression vector. Each transfection was performed at least
thrice independently and the mean values are plotted with their standard
errors (±s.e., vertical bars). Extracts for luciferase assays were resolved
using 12% SDS–PAGE, transferred to a PVDF membrane, and
immunoblotted with anti-Oct-4 (C-20) (middle panel) or anti-EGFP
(bottom panel) antibodies, as indicated.
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Glutathione-S-transferase fusions of EWS-Oct-4B and EWS-Oct-4
were expressed in Escherichia coli, purified, and coupled to
glutathione–Sepharose beads. To quantify the amount of each
protein used, affinity-purified GST, GST-EWS-Oct-4B, and GST-
EWS-Oct-4 proteins were fractionated by SDS–PAGE, transferred
to a PVDF membrane, and immunoblotted with an anti-GST
antibody (B-14, Santa Cruz Biotechnology) (Figure 4A). Electro-
phoretic mobility shift assays were then performed by keeping the
concentration of the Oct-4 probe constant and varying the amount
of input protein. Protein–DNA complexes were formed with both
EWS-Oct-4B and EWS-Oct-4 proteins (Figure 4B lanes 4–6 and 7–
9), whereas GST alone hardly bound at all (Figure 4A lanes 1–3).
Binding was specific, as these complexes were displaced by a 100-
fold excess of cold oligonucleotide containing the Oct-4-binding
site, but not by a 100-fold excess of cold mutant oligonucleotide
containing a mutant Oct-4-binding sequence that is not recognised
by Oct-4 (data not shown). These results indicate that, although
EWS-Oct-4B shares its C-terminal portion with the human Oct-4B
isoform, the DNA-binding specificity of EWS-Oct-4B resembles
that previously defined for Oct-4A.
EWS (NTD)
B is a less-potent transcriptional activation
domain than EWS (NTD)
Although protein–DNA complexes were formed with both
EWS-Oct-4B and EWS-Oct-4 proteins (Figure 4) and both are
localised to the nucleus (Figure 2), EWS-Oct-4B was a less-potent
transcriptional activator than EWS-Oct-4 (Figure 3), suggesting
that this difference could be due to the differences in their NTD s.
To verify this hypothesis, we created fusion proteins in which the
GAL4 DNA-binding domain was fused to the EWS (NTD) of EWS-
Oct-4 or to the EWS (NTD)
B of EWS-Oct-4B (Figure 5A). The pG5
luc reporter contains five GAL4 DNA-binding sites upstream of
the TATA box and was used as a reporter in these experiments.
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Figure 4 DNA-binding property of the EWS-Oct-4B chimera.
(A) Immunoblot analysis of EWS-Oct-4B and EWS-Oct-4 to quantify
GST fusion proteins. The GST-EWS-Oct-4 fusion proteins used in EMSAs
were fractionated on 10% SDS–PAGE and visualised by western blotting
with an anti-GST antibody (B-14, Santa Cruz Biotechnology). (B) EMSAs
of the DNA-binding properties of EWS-Oct-4B and EWS-Oct-4. The
EMSAs were performed using recombinant GST (lane 1, 0.15mg; lane 2,
0.45mg; lane 3, 1.35mg), GST-EWS-Oct-4 (lane 4, 0.15mg; lane 5, 0.45mg;
lane 6; 1.35mg), or GST-EWS-Oct-4B (lane 7, 0.15mg; lane 8, 0.45mg;
lane 9, 1.35mg), and radiolabeled probe, as described in Materials and
Methods. The recombinant proteins used in each EMSA are indicated
above the gel. Protein–DNA complexes were resolved on non-denaturing
4% polyacrylamide (acrylamide:bisacrylamide ratio, 37:1) gels run at 41Ci n
0.5  TBE (44.5mM Tris-HCl, 44.5mM boric acid, 1mM EDTA). The
positions of free probe and protein–DNA complexes are indicated.
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Figure 5 Transactivation potential of EWS (NTD)
B.( A) Schematic
representation of the GAL4-fusion expression plasmids used in this study.
The expression vectors driving the production of GAL4-EWS (NTD) or
GAL4-EWS (NTD)
B are shown. GAL4, GAL4 DNA-binding domain; EWS
(NTD), EWS N-terminal domain of EWS-Oct-4; EWS (NTD)
B, EWS
N-terminal domain of EWS-Oct-4B. (B) Comparison of transactivation
potential of EWS (NTD)
B. The reporter plasmid, 5  Gal4 TATA luc, was
cotransfected with GAL4-EWS (NTD) or GAL4-EWS (NTD)
B into
293T cells (top panel). Luciferase activity was expressed as fold activation
relative to the basal level observed with the reporter plasmid and the
GAL4 DNA-binding domain alone (lane 1). Each transfection was
performed independently at least thrice and the mean values are plotted
with their standard errors (±s.e., vertical bars). Extracts for luciferase assays
were resolved using 12% SDS–PAGE, transferred to a PVDF membrane,
and immunoblotted with anti-GAL-4 (RK5C1) (middle panel) or anti-EGFP
(bottom panel) antibodies as indicated.
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drives the synthesis of only the GAL4 DNA-binding domain, had
no significant effect on the level of luciferase produced from
pG5 luc when transfected into 293T cells (Figure 5B, lane 1).
Interestingly, pGAL4-EWS (NTD) strongly activated luciferase
production from pG5 luc by 25-fold (Figure 5B, lane 3), indicating
that the EWS (NTD) of the EWS-Oct-4 protein has an intrinsic
transcriptional activation property. On the other hand, the EWS
(NTD)
B of EWS-Oct-4B (lane 5) activated luciferase production
from pG5 luc by 15-fold when fused to the DNA-binding domain of
GAL4. These results show that the EWS (NTD)
B of EWS-Oct-4B is
capable of activating transcription, but is a less potent transacti-
vator than the EWS (NTD) of EWS-Oct-4.
Multiple domains are important for EWS-Oct-4B function
To define the critical regions within EWS-Oct-4B required
for transactivation, we performed transient transfection experi-
ments using flag-tagged EWS-Oct-4B deletions. The structures
of the EWS-Oct-4B deletion mutants are shown schematically
in Figure 6A. The data in the right panel show that deletion of the
EWS (NTD)
B (named as EWS-Oct-4B (DEWS)) or a mutation of
the POU DNA-binding domain (EWS-Oct-4B (V313P), which
harbours a missense mutation in the POU DNA-binding domain
converting
313Val to
313Pro) abolished transactivation activity,
whereas removal of the CTD of EWS-Oct-4B (EWS-Oct-4B
(DCTD)) reduced activity. We interpret these results to indicate
that EWS (NTD)
B and CTD, as well as the DNA-binding activity of
EWS-Oct-4B, are important for its full transactivation potential.
The expression levels of all mutant proteins were examined by
western blotting (Figure 6B, top panel). EGFP expression served
as an internal control for monitoring transfection efficiency
(Figure 6B, bottom panel).
Regulation of endogenous Oct-4 downstream target genes
by EWS-Oct-4B
To determine whether ectopic expression of EWS-Oct-4B could
modulate the expression of endogenous Oct-4 downstream target
genes such as fibroblast growth factor-4 (fgf-4) (Ambrosetti et al,
1997; Wang et al, 2003) and nanog (Kuroda et al, 2005; Rodda et al,
2005), we stably transfected Oct-4-null ZHBTc4 ES cells with
pCAG-IP/EGFP and pCAG-IP/EWS-Oct-4B constructs (Figure 7A).
We used the ZHBTc4 ES cell line because EWS-Oct-4B-positive
human epithelial tumour cell lines or their equivalents are not
available. In addition, it was convenient to introduce expression of
the EWS-Oct-4B gene ectopically, because both the endogenous
alleles of Oct-4 have been inactivated by gene targeting in the
ZHBTc4 ES cell line, which also harbours the tetracycline-repres-
sible mouse Oct-4 transgene (Niwa et al, 2000).
The amount of EWS-Oct-4B protein was determined by western
blotting. The stable cell line carrying EWS-Oct-4B produced the
EWS-Oct-4B protein as an EGFP fusion form (Figure 7B, lane 2).
No EWS-Oct-4B-EGFP protein was detected in the control cell line
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Figure 6 Functional regions of EWS-Oct-4B. (A) Transcriptional properties of EWS-Oct-4B deletion mutants. Shown on the left are schematic
representations of EWS-Oct-4B deletion constructs. A reporter plasmid, pOct-4(10 ) TATA luc, was cotransfected into 293T cells with various flag-tagged
EWS-Oct-4B mutants. Relative transcriptional activation values are shown on the right as mean increases±s.e. relative to a value of 100% for transfection of
EWS-Oct-4B. The results are the means of three independent experiments performed in duplicate. (B) Immunoblot analysis showing expression of the
EWS-Oct-4B deletion mutants in transiently transfected cells. Total cell lysates were fractionated by 12% SDS–PAGE and visualised by western blotting with
anti-Flag (M2, Sigma, top panel) or anti-EGFP (Invitrogen Molecular Probes, bottom panel) antibodies. The positions of pre-stained molecular weight markers
(New England Biolabs, Hitchin, UK) are indicated to the left (kDa). Lane 1, empty vector; lane 2, EWS-Oct-4B; lane 3, EWS-Oct-4B (DEWS); lane 4, EWS-
Oct-4 (DCTD); and lane 5, EWS-Oct-4B (V313P).
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nanog was detected in tetracycline-treated ZHBTc4 ES cells
expressing the EWS-Oct-4B chimeric protein (Figure 7C, lane 2),
but not in treated cells expressing the EGFP vector alone
(Figure 7C, lane 1). Thus, EWS-Oct-4B is capable of activating
Oct-4 downstream target genes in vivo.
ZHBTc4 ES cells harbouring EWS-Oct-4B have
tumourigenic growth potential in nude mice
Finally, we examined the ability of the EWS-Oct-4B chimeric
protein to induce tumours in nude mice. Nude mice were exposed
to the tetracycline analogue, doxycycline, in their drinking water
for 2 weeks before injection of EWS-Oct-4B cells, and the exposure
was continued thereafter. As shown in Figure 8, all six mice
injected with ZHBTc4 cells expressing EWS-Oct-4B developed
large tumours within a relatively short latent period, showing that
EWS-Oct-4B functions as an oncogene, at least as efficiently as
EWS-Oct-4 (Lee et al, 2007) or Oct-4 (Gidekel et al, 2003). The
same results were obtained with two other independent clones of
ZHBTc4 cells expressing EWS-Oct-4B (data not shown). These
results show that, similar to EWS-Oct-4 (Lee et al, 2007),
overexpression of the EWS-Oct-4B chimeric protein is sufficient
to induce tumourigenesis in nude mice.
DISCUSSION
Chromosome translocation is an important mechanism for crea-
ting oncogenes, and is the one that occurs frequently in human
neoplasms (Rabbitts and Stocks, 2003). In this report, we have
characterised the EWS-Oct-4B fusion protein, an alternative form
of fusion between the EWS and Oct-4 genes. This product is
produced by chromosome translocation and is found in two types
of human epithelial tumours (Moller et al, 2008). These tumours
contain a characteristic t(6;22)(p21;q12) translocation, which
results in the fusion of the amino terminal domain of EWS with
the carboxy-terminal domain of human Oct-4. Here, we show that
the alternative fusion protein, EWS-Oct-4B, is a nuclear protein
that binds DNA with a sequence specificity indistinguishable from
that of the parental Oct-4 or the original EWS-Oct-4 fusion
product. In addition, this fusion gene is another powerful
transforming gene, although it encodes a less-potent transcrip-
tional activator than EWS-Oct-4.
The tumourigenic potential of the chimeric EWS-Oct-4B gene
product is consistent with the idea that it has a crucial role in the
formation of hidradenomas or mucoepidermoid carcinomas in
humans. Although the EWS-Oct-4B form is revealed as a less-
potent transcriptional activator than EWS-Oct-4 (Figure 3), the
efficient and rapid growth of ZHBTc4 ES cells expressing EWS-
Oct-4B protein in nude mice indicates that EWS-Oct-4B is also a
potent oncogene (Figure 8). In human cancer, genes involved in
controlling cell proliferation and survival are altered in ways that
change either the behaviour or the amounts of proteins they
produce. The chromosome rearrangement between EWS and Oct-4
genes suggests the reactivation of silencing Oct-4 gene expression
as a form of EWS-Oct-4B fusion. Accumulating evidence shows
that anomalous expression of Oct-4 is involved in several human
cancers. For example, the introduction of Oct-4 into Swiss 3T3 cells
causes their tumourigenic transformation and produces tumours
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Figure 7 Transcriptional activation of Oct-4 downstream target genes by EWS-Oct-4B in vivo.( A) Schematic representation of the expression vectors.
Expression vector pCAG-IP/EWS-Oct-4B-EGFP corresponds to EWS-Oct-4B fused to EGFP. The pCAG-IP/EGFP expression vector was used as a control.
The CAG expression units (CAG) are indicated by shaded boxes, EWS-Oct-4B is represented by an open box, and EGFP is indicated by solid boxes.
(B) Immunoblot analysis of EWS-Oct-4B expression in stably transfected ZHBTc4 ES cells. Total cell lysates (60mg protein) were fractionated by 12% SDS–
PAGE and visualised by western blotting with anti-EGFP (Invitrogen Molecular Probes, top panel) or anti-GAPDH (V-18, Santa Cruz Biotechnology, lower
panel) antibodies. (C) Induction of Oct-4 downstream target genes by EWS-Oct-4B in vivo. Northern blot analyses of fgf-4 and nanog mRNAs were
performed in ZHBTc4 ES cells expressing vector (lane 1) or EWS-Oct-4B fusion proteins (lane 2). Total RNA was fractionated on a 6% formaldehyde–1.5%
agarose gel, transferred to a nylon membrane, and probed using mouse fgf-4 (upper panel) or nanog (second panel) cDNAs, as described in Materials and
Methods. Ethidium bromide (EtBr) staining of the agarose gel used for northern blotting shows that equal amounts of total RNA were loaded in each lane
(lower panel). The stable cell lines from which the total RNAs used in the northern blot analysis were derived are shown above the panel.
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have reported that Oct-4 is expressed in human tumours, including
testicular germ cell tumours and breast carcinomas, and has a part
in human cancer development (Jin et al, 1999; Monk and Holding,
2001; Gidekel et al, 2003; Looijenga et al, 2003). In addition, the
activation of Oct-4 in somatic tissues of adult mice, using a
doxycycline-dependent expression system, results in dysplastic
growth in epithelial tissues (Hochedlinger et al, 2005), indicating
that abnormal expression of Oct-4 may be the cause of
tumourigenesis in somatic tissues.
Alternative splicing of human Oct-4 mRNA gives rise to two
different protein isoforms designated as Oct-4A and Oct-4B
(Takeda et al, 1992). These isoforms are composed of 360 and
265 amino acids, respectively, of which the 225 amino acids at the
carboxy-termini are identical. The CTDs (71 amino acids) of
human Oct-4A and Oct-4B are identical, but the Oct-4B POU
domain (total 154 amino acids) lacks two amino acids of the
N-terminal sequence of the Oct-4A POU domain (total 156 amino
acids). Outside these regions, Oct-4B has little similarity to Oct-4A.
The C-terminal part of EWS-Oct-4B, isolated in a hidradenoma of
the skin and a mucoepidermoid carcinoma of the salivary gland
(Moller et al, 2008), was found to be more similar to that of Oct-4B
than to that of Oct-4A. Similar to Oct-4B, the POU DNA-binding
domain of EWS-Oct-4B lacks two amino acids of the N-terminal
sequence of the EWS-Oct-4 POU domain. Interestingly, the human
Oct-4B isoform does not bind to DNA carrying the typical Oct-4
consensus-binding sequence, is mainly localised to the cytoplasm,
and does not activate transcription from an Oct-4-dependent
promoter (Lee et al, 2006). However, unlike human Oct-4B, EWS-
Oct-4B is a nuclear protein (Figure 2) that binds DNA with a
sequence specificity indistinguishable from that of Oct-4A
(Figure 4) and shows a potent transcriptional activation potential
(Figures 3 and 7). Therefore, our data imply that the DNA-binding
and transactivation properties of EWS-Oct-4B and Oct-4B differ,
although there are structural similarities between these two
proteins.
Although the DNA-binding specificity of EWS-Oct-4B resembles
that previously defined for EWS-Oct-4 (Figure 4), we show that
EWS-Oct-4B is a less-potent transactivator than EWS-Oct-4
(Figure 3). According to our previous report, the EWS NTD of
EWS-Oct-4 contributes to its transcriptional activation function by
providing a novel activation domain (Lee et al, 2007), which
suggests that the difference in transactivation potential between
EWS-Oct-4B and EWS-Oct-4 could be due to differences in their
EWS NTDs. Consistent with this hypothesis, the EWS (NTD)
B of
EWS-Oct-4B was capable of activating transcription, but was a
less-potent transactivator than the EWS (NTD) of the EWS-Oct-4
fusion protein (Figure 5). The EWS NTD contains a large number
of tyrosine, glutamine, alanine, serine, threonine, glycine, and
proline residues, some of which are organised in a repeated and
degenerate peptide motif with a frequently recurring serine–
tyrosine dipeptide (NSYGQQS) that shares homology with the CTD
of the large subunit of eukaryotic RNA polymerase II (Delattre
et al, 1992). The amino acid sequence of the EWS (NTD) does not
suggest any particular discrete region that might be important for
transcriptional activation (Kim et al, 1998b); thus, it may be
possible that the entire EWS (NTD) is necessary for its full
transactivation potential.
It remains to be determined whether the structural differences
between EWS-Oct-4B and EWS-Oct-4 are clinically significant in
human cancer. In the case of Ewing’s sarcoma, there are up to 18
possible types of in-frame EWS-Fli-1 fusion transcripts and most
of these isotypes have been observed in vivo (Zucman et al, 1993).
Interestingly, regardless of tumour site, stage, or size, the survival
rate of Ewing’s sarcoma patients with type I EWS-Fli-1 fusion is
markedly better than those in whom Ewing’s sarcoma carries other
types of EWS-Fli-1 fusions (Zoubek et al, 1996; de Alava et al,
1998; Lin et al, 1999). Although we have shown that EWS-Oct-4B
regulates the expression of fgf-4 and nanog, which are known
potent mitogens (Figure 7), it remains to be seen whether the
activation of fgf-4 or nanog through EWS-Oct-4B is sufficient to
produce the neoplastic phenotype found in the two types of
epithelial tumours, hidradenoma of the skin and mucoepidermoid
carcinoma of salivary glands. The functional characterisations of
both EWS-Oct-4 and EWS-Oct-4B isoforms in human cancers
should be of potential medical interest.
Recently, it was reported that abnormal expression of the
EWS-Oct-4 chimera by chromosomal translocation induces an
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Figure 8 Characterisation of the effects of ZHBTc ES cells expressing EWS-Oct-4B in nude mice. (A) Effects of EWS-Oct-4B expression on the
development of tumours in nude mice. Approximately 0.6 10
7 Oct-4-null ZHBTc4 ES cells expressing EWS-Oct-4B-EGFP or EGFP, were suspended in
100ml PBS and injected into 5-week-old Balb/c athymic nude mice. Tumour development was observed and photographs were taken 26 days after injection.
(B) Weight of tumours from nude mice injected with Oct-4-null ZHBTc ES cells expressing EWS-Oct-4B. Tumour weight in individual animals was
measured at 26 days after injection (n¼6) and is plotted as mean increases±s.e.
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sincomplete mesenchymal-to-embryonic transition (Makino et al,
2009). Because EWS-Oct-4 is a nuclear protein that binds DNA
with a sequence specificity indistinguishable from that of the
parental Oct-4 protein (Lee et al, 2007), and because ectopic
expression of Oct-4 also causes dysplasia by inhibiting progenitor
cell differentiation (Hochedlinger et al, 2005), it seems reasonable
to speculate that the fusion of EWS NTD to the Oct-4 DNA-binding
domain may produce a transforming chimeric product that
inhibits cellular differentiation. Despite its reduced activity as a
transcriptional activator, EWS-Oct-4B also regulated Oct-4 down-
stream target genes the promoters of which contain potential Oct-
4-binding sites (Figure 7). Because the properties of EWS-Oct-4B
are very similar to those of EWS-Oct-4, it would be interesting to
investigate whether abnormal expression of EWS-Oct-4B in two
types of epithelial tumours, hidradenoma of the skin and
mucoepidermoid carcinoma of salivary glands, also contributes
to the induction of the incomplete embryonic transition.
In conclusion, this study provides evidence that the EWS-Oct-4B
fusion protein is an oncogene and that it is necessary for tumouri-
genesis. On the basis of our findings, we suggest that additional
genes may cooperate with EWS-Oct-4 or be required for tumour
progression. Although EWS-Oct-4B is a less-potent transactivator
than EWS-Oct-4, it probably contributes to oncogenesis by
activating key Oct-4 downstream target genes, such as fgf-4 and
nanog. It will be interesting to determine which downstream target
gene(s) is/are critical for tumourigenesis, and whether EWS-Oct-
4B collaborates with this/these gene(s) to generate human
epithelial tumours.
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